Almagor Y, Feld S, Kiemeneij F, Serruys P W, Morice M C, Colombo A, Macaya C, Guermonprez J L, Marco J, Erbel R, Penn I M, Bonan R, Leon M B
Shaare Zedek Medical Center, Jerusalem, Israel.
J Am Coll Cardiol. 1997 Oct;30(4):847-54. doi: 10.1016/s0735-1097(97)00269-6.
The purpose of this study was to determine the feasibility, safety and efficacy of elective and urgent deployment of the new intravascular rigid-flex (NIR) stent in patients with coronary artery disease.
Stent implantation has been shown to be effective in the treatment of focal, new coronary stenoses and in restoring coronary flow after coronary dissection and abrupt vessel closure. However, currently available stents either lack flexibility, hindering navigation through tortuous arteries, or lack axial strength, resulting in suboptimal scaffolding of the vessel. The unique transforming multicellular design of the NIR stent appears to provide both longitudinal flexibility and radial strength.
NIR stent implantation was attempted in 255 patients (341 lesions) enrolled prospectively in a multicenter international registry from December 1995 through March 1996. Nine-, 16- and 32-mm long NIR stents were manually crimped onto coronary balloons and deployed in native coronary (94%) and saphenous vein graft (6%) lesions. Seventy-four percent of patients underwent elective stenting for primary or restenotic lesions, 21% for a suboptimal angioplasty result and 5% for threatened or abrupt vessel closure. Fifty-two percent of patients presented with unstable angina, 48% had a previous myocardial infarction, and 45% had multivessel disease. Coronary lesions were frequently complex, occurring in relatively small arteries (mean [+/-SD] reference diameter 2.8 +/- 0.6 mm). Patients were followed up for 6 months for the occurrence of major adverse cardiovascular events.
Stent deployment was accomplished in 98% of lesions. Mean minimal lumen diameter increased by 1.51 +/- 0.51 mm (from 1.09 +/- 0.43 mm before to 2.60 +/- 0.50 mm after the procedure). Mean percent diameter stenosis decreased from 61 +/- 13% before to 17 +/- 7% after intervention. A successful interventional procedure with < 50% diameter stenosis of all treatment site lesions and no major adverse cardiac events within 30 days occurred in 95% of patients. Event-free survival at 6 months was 82%. Ninety-four percent of surviving patients were either asymptomatic or had mild stable angina at 6 month follow-up.
Despite unfavorable clinical and angiographic characteristics of the majority of patients enrolled, the acute angiographic results and early clinical outcome after NIR stent deployment were very promising. A prospective, randomized trial comparing the NIR stent with other currently available stents appears warranted.
本研究旨在确定在冠心病患者中选择性和紧急部署新型血管内刚柔(NIR)支架的可行性、安全性和有效性。
支架植入已被证明在治疗局灶性、新发性冠状动脉狭窄以及冠状动脉夹层和血管突然闭塞后恢复冠状动脉血流方面是有效的。然而,目前可用的支架要么缺乏柔韧性,妨碍在迂曲动脉中的导航,要么缺乏轴向强度,导致血管的支架支撑效果欠佳。NIR支架独特的可变形多细胞设计似乎兼具纵向柔韧性和径向强度。
1995年12月至1996年3月期间,前瞻性纳入多中心国际登记处的255例患者(341处病变)尝试植入NIR支架。将9毫米、16毫米和32毫米长的NIR支架手动压接到冠状动脉球囊上,并部署在原生冠状动脉病变(94%)和大隐静脉桥病变(6%)中。74%的患者因原发性或再狭窄病变接受选择性支架置入,21%因血管成形术效果欠佳接受治疗,5%因血管受到威胁或突然闭塞接受治疗。52%的患者表现为不稳定型心绞痛,48%有既往心肌梗死病史,45%有多支血管病变。冠状动脉病变通常较为复杂,多发生于相对较细的动脉(平均[±标准差]参考直径2.8±0.6毫米)。对患者进行6个月的随访,观察主要不良心血管事件的发生情况。
98%的病变成功完成支架部署。平均最小管腔直径增加了1.51±0.51毫米(从术前的1.09±0.43毫米增至术后的2.60±0.50毫米)。平均直径狭窄百分比从术前的61±13%降至干预后的17±7%。95%的患者在所有治疗部位病变直径狭窄<50%且30天内无重大不良心脏事件的情况下,介入手术成功。6个月时无事件生存率为82%。94%存活的患者在6个月随访时无症状或有轻度稳定型心绞痛。
尽管大多数纳入患者的临床和血管造影特征不佳,但NIR支架部署后的急性血管造影结果和早期临床结局很有前景。开展一项将NIR支架与其他现有支架进行比较的前瞻性随机试验似乎是必要的。